RecruitingPhase 3NCT05997979

Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children

Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch for the Treatment of Chronic Postsurgical or Post-traumatic Neuropathic Pain: a Randomized Placebo Controlled Study in Children Aged 12 to 17-y

Sponsor

University Hospital, Brest

Enrollment

46 participants

Start Date

Mar 5, 2024

Study Type

INTERVENTIONAL

Conditions

Chronic Pain Neuropathic Pain

Summary

This study concerns children aged to 12 to 17-years with local chronic neuropathic pain after trauma or surgery. It is a multicentric randomized controlled superiority trial in parallel arms : * experimental arm: Capsaicin 8% cutaneous patch * controlled arm : Hydrocolloid dressing Treatment with capsaicin application is realized at baseline, and repeated 3 months after the first patch application if needed. Tolerance is assessed during each application and by phone call in following days until stop of cold need. Efficacy is assessed monthly by clinical consultation until the end of the study (month 4).

Eligibility

Min Age: 12 YearsMax Age: 17 Years

Inclusion Criteria7

Children aged 12 to 17 years (lower age limit of 12 has been chosen to ensure NPSI full filling).
Male or female.
Persistent neuropathic pain more than 3 months after surgery or trauma despite treatment following recommendations.
Neuropathic pain is defined as a DN4 score equal to or greater than 3/7 or 4/10, and localized in a nerve territory explained by the surgery or the trauma.
Treatment, survey and follow up must be realized in an identified investigating center of the study
For patients of childbearing potential: use of an adequate method of contraception* during the course of the study through 48 hours after the last patch application (girls of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first patch application).
Adequate contraception includes sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

Exclusion Criteria10

Intellectual deficiency not allowing full filling of NPSI.
Insufficient command of the French language to full fill NPSI and other evaluation tools.
Parents' refusal of consent.
Minor patients' opposition.
Underlying neurological disease.
Ongoing neurotoxic treatment.
Already treated by capsaicin.
Cutaneous lesion on pain area.
Patient presenting a pain area on the face, above the hairline of the scalp, and/or in proximity to mucous membranes
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Qutenza SmPC.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCapsaicin 8% patch

Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.

DEVICEHydrocolloid dressing

Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.